Tags : Ionis

Ionis to Acquire Remaining Stake in Akcea Therapeutics for $18.5/share

Shots: Ionis will acquire all the outstanding shares of Akcea common stock it does not already own, ~24%, for $18.15/share in cash, making a total deal value as $500M. The transaction is expected to be completed in Q4’20 Following the completion of the acquisition, Ionis will get access to Akcea’s rich pipeline and commercial products […]Read More

Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study

Shots: The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos. The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides, ANGPTL3, apoC-III, VLDL-C, non-HDL cholesterol, no reduction in liver fat and is well tolerated AKCEA-ANGPTL3-LRx is […]Read More

Biogen Signs an Exclusive License Agreement with Ionis for IONIS-MAPTRx

Shots: Ionis to get $45M as license fee, additional milestone up to $155M plus royalties on sales and will also be responsible for P-I trial assessing IONIS-MAPTRx in patients with mild AD. Biogen will take care of all subsequent studies plus further development, including regulatory filings, and commercialization In 2012, Ionis and Biogen collaborated to […]Read More

GSK Exercises Its Option to License Ionis’ Antisense Therapy for

Shots: Ionis to receive ~$262M milestones including $25M license fee with royalties on sales of products. GSK to exercise its option to license program following positive P-II results and will be responsible for all development, regulatory, commercialization activities and its costs  In Mar’2010, GSK and Ionis collaborated on RNA therapies for rare and infectious diseases […]Read More

ProQR Signs Exclusive Worldwide License Agreement with Ionis for IONIS-RHO-2.5

Shots: Ionis Pharmaceuticals will receive an upfront payment in ordinary shares $2.5M, $22.23/share representing 20% premium plus milestones payments and 20% royalties on net sales of QR-1123. ProQR to get WW license rights for Ionis’ IONIS-RHO-2.5 Candidate In 2019, ProQR plans onset of P-I/II trial for QR-1123 in autosomal dominant retinitis pigmentosa (adRP) with awaited […]Read More

Roche and Ionis Collaborates to Develop Ionis’s IONIS-FB-LRx to Treat

Shots: Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for conducting P-II trial for IONIS-FB-LRx in patients with Geographic Atrophy (GA) Under the agreement, Roche has option to license IONIS-FB-LRx post trial completion and will […]Read More